Search
Tinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalTinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. … It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally.
mRNA-1010
go.drugbank.com/drugs/DB22484Approved[L64058] Unlike conventional egg- or cell-based inactivated influenza vaccines, mFLUSIVA is built on the mRNA platform and is manufactured without an egg- or cell-based process. … MFLUSIVA (influenza vaccine, mRNA), also known by its development code mRNA-1010, is a messenger RNA–based vaccine for active immunization against seasonal influenza.
Mibefradil
go.drugbank.com/drugs/DB01388ApprovedWithdrawnMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalEplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative
Categories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 SubstratesPhenolsulfonphthalein
go.drugbank.com/drugs/DB13212ExperimentalPhenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories. … Phenolsulfonphthalein is being investigated for use clinically due to its weak estrogen mimicking actions [A174964].
Categories: Tests for Renal Function and Ureteral InjuriesVorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersOxycodegol
go.drugbank.com/drugs/DB14146InvestigationalNektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263] … Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263].
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational_C. botulinum_ is known to produce toxins that can cause botulism in humans. … DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent.
Xenon Xe-129
go.drugbank.com/drugs/DB17386ApprovedInvestigational[A255183] In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation.